{
    "response": "**Overall Treatment Decision:** Yes\u2014treat\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute optic neuritis with RAPD and reduced acuity Early steroids hasten visual recovery First-line for MS/MOGAD/NMOSD relapses once infection is excluded\n\n*   **Treatment:** Proton pump inhibitor\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastric protection during high-dose steroids\n\n*   **Treatment:** Blood glucose monitoring with correctional insulin if needed\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Steroid-induced hyperglycaemia risk\n\n*   **Treatment:** Plasma exchange (5\u20137 exchanges)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Escalation if severe deficit or no improvement within 5\u20137 days of steroids Indicated in AQP4-IgG positive attacks or steroid-refractory optic neuritis\n\n*   **Treatment:** Disease-modifying therapy for MS (e.g., ocrelizumab) or NMOSD-directed therapy (e.g., rituximab/satralizumab) based on results\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate only after diagnostic confirmation Choice depends on antibody status and MRI/CSF findings\n\n*   **Treatment:** Aspirin and vascular risk management\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Only if imaging confirms ischaemic aetiology\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute optic neuritis with RAPD and reduced acuity\", \"Early steroids hasten visual recovery\", \"First-line for MS/MOGAD/NMOSD relapses once infection is excluded\"]}, {\"treatment\": \"Proton pump inhibitor\", \"timing\": \"Start Now\", \"reasons\": [\"Gastric protection during high-dose steroids\"]}, {\"treatment\": \"Blood glucose monitoring with correctional insulin if needed\", \"timing\": \"Start Now\", \"reasons\": [\"Steroid-induced hyperglycaemia risk\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 exchanges)\", \"timing\": \"Delay\", \"reasons\": [\"Escalation if severe deficit or no improvement within 5\\u20137 days of steroids\", \"Indicated in AQP4-IgG positive attacks or steroid-refractory optic neuritis\"]}, {\"treatment\": \"Disease-modifying therapy for MS (e.g., ocrelizumab) or NMOSD-directed therapy (e.g., rituximab/satralizumab) based on results\", \"timing\": \"Delay\", \"reasons\": [\"Initiate only after diagnostic confirmation\", \"Choice depends on antibody status and MRI/CSF findings\"]}, {\"treatment\": \"Aspirin and vascular risk management\", \"timing\": \"Delay\", \"reasons\": [\"Only if imaging confirms ischaemic aetiology\"]}]"
}